Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Apr 18;2012(4):CD005385.
doi: 10.1002/14651858.CD005385.pub3.

Recombinant human activated protein C for severe sepsis in neonates

Ranjit I Kylat  1 , Arne Ohlsson
Affiliations

Recombinant human activated protein C for severe sepsis in neonates

Ranjit I Kylat et al. Cochrane Database Syst Rev. .

Abstract

Background: Sepsis is a common problem in preterm and term infants. The incidence of neonatal sepsis has declined, but mortality remains high. Recombinant human activated protein C (rhAPC) possess a broad spectrum of activity modulating coagulation and inflammation. In septic adults it may reduce mortality, but no significant benefit has been reported in children with severe sepsis.

Objectives: To determine whether treatment with rhAPC reduces mortality and/or morbidity in neonatal sepsis.

Search methods: For this update searches were carried out in May 2011 of the Cochrane Central Register of Controlled Trials (The Cochrane Library), MEDLINE, EMBASE, CINAHL, and abstracts of annual meetings of the Pediatric Academic Societies. Doctoral dissertations, theses and the Science Citation Index for articles on activated protein C were searched. No language restriction was applied.

Selection criteria: Randomized or quasi-randomized trials, assessing the efficacy of rhAPC compared to placebo or no intervention as an adjunct to antibiotic therapy of suspected or confirmed severe sepsis in term and preterm infants less than 28 days old. Eligible trials should report at least one of the following outcomes: mortality during initial hospital stay, neurodevelopmental assessment at two years of age or later, length of hospital stay, duration of ventilation, chronic lung disease, periventricular leukomalacia, intraventricular haemorrhage, necrotizing enterocolitis, bleeding, and any other adverse events.

Data collection and analysis: Review authors were to independently evaluate the articles for inclusion criteria and quality, and abstract information for the outcomes of interest. Differences were to be resolved by consensus. The statistical methods were to include relative risk, risk difference, number needed to treat to benefit or number needed to treat to harm for dichotomous and weighed mean difference for continuous outcomes reported with 95% confidence intervals. A fixed effect model was to be used for meta-analysis. Heterogeneity tests, including the I(2) statistic, were to be performed to assess the appropriateness of pooling the data.

Main results: No eligible trials were identified. In October 2011 rhAPC (Xigris®) was withdrawn from the market by Eli Lilly due to a higher mortality in a trial among adults. Xigris® (DrotAA)( rhAPC) should no longer be used in any age category and the product should be returned to the distributor.

Authors' conclusions: Despite the scientific rationale for its use, there is insufficient data to use rhAPC for the management of severe sepsis in newborn infants. Due to the results among adults with lack of efficacy, an increase in bleeding and resulting withdrawal of rhAPC from the market, neonates should not be treated with rhAPC and further trials should not be conducted.

PubMed Disclaimer

Conflict of interest statement

None

Update of

References

References to studies excluded from this review

Albuali 2005 {published data only}
    1. Albuali WH, Singh RN, Fraser DD, Scott LA, Kornecki A. Drotrecogin alfa (activated) treatment in a neonate with sepsis and multi organ failure. Saudi Medical Journal 2005;26:1289‐92. - PubMed
Barton 2004 {published data only}
    1. Barton P, Kalil AC, Nadel S, Goldstein B, Okhuysen‐Cawley R, Brilli RJ, et al. Safety, pharmacokinetics, and pharmacodynamics of drotrecogin alfa (activated) in children with severe sepsis. Pediatrics 2004;113:7‐17. - PubMed
Eli Lilly 2005a {unpublished data only}
    1. Eli Lilly. Xigris®‐ results in pediatric patients in the global ENHANCE trial: An overview. Lilly Research Labratories. Medical Information on Xigris® for physicians 2005.
Eli Lilly 2005b {unpublished data only}
    1. Eli Lilly. Xigris (drotrecogin alfa [activated]: The RESOLVE Trial. Eli Lilly: Xigris: Medical information for physicians.
Frommhold 2005 {published data only}
    1. Frommhold D, Birle A, Linderkamp O, Zilow E, Poschl J. Drotrecogin alpha (activated) in neonatal septic shock. Scandinavian Journal of Infectious Disease 2005;37:306‐8. - PubMed
Lokeshwar 2006 {published data only}
    1. Lokeshwar MR, Singhal T, Udani SV, Kapadia FN. Treatment of acute infectious purpura fulminans with activated protein C. Indian Pediatrics 2006;43:535‐8. - PubMed
Manco‐Johnson 2004 {published data only}
    1. Manco‐Johnson MJ, Knapp‐Clevenger R. Activated protein C concentrate reverses purpura fulminans in severe genetic protein C deficiency. Journal of Pediatric and Hematological Oncology 2004;26:25‐7. - PubMed
Martinon‐Torres 2004 {published data only}
    1. Martinon‐Torres F, Iglesias Meleiro JM, Fernandez Sanmartin M, Rodriquez Nunez A, Martinon Sanchez JM. Recombinant human activated protein C in the treatment of children with meningococcal purpura fulminans [Proteìna C activada humana recombinante en el tratmiento de ninos con purpura fulminante meningococica]. Anales de Pediatria (Barcelona, Spain) 2004;61:261‐5. - PubMed
Nadel 2007 {published data only}
    1. Nadel S, Goldstein B, Williams MD, Dalton H, Peters M, Macias WL, et al. Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial. Lancet 2007;369:836‐43. - PubMed
Rawicz 2002 {published data only}
    1. Rawicz M, Sitkowska B, Rudzinska I, Kornacka MK, Bochenski P. Recombinant human activated protein C for severe sepsis in a neonate. Medical Science Monitor 2002;8:CS90‐4. - PubMed
Sajan 2004 {published data only}
    1. Sajan I, Da‐Silva SS, Dellinger RP. Drotrecogin alfa (activated) in an infant with gram‐negative septic shock. Journal of Intensive Care Medicine 2004;19:51‐5. - PubMed
Strohler 2004 {published data only}
    1. Strohler B, Patel N, Grzeszczak M, Churchwell K. Use of activated protein C in a preterm neonate with Group B Streptococcal sepsis. Pediatric Critical Care Medicine 2004;5:512.
Verre 2005 {published data only}
    1. Verre M, Barozzi E, Piccirillo M, Tancioni F, Tiburzi S, Varano M. Use of activated protein C in a case of paediatric septic shock. Minerva Pediatrica 2005;57:429‐32. - PubMed
Wyss 2004 {published data only}
    1. Wyss VL, Cunneen J, Short MA, Turlo MA. Assessment of severe sepsis in children: Experiences from pediatric patients receiving Drotrecogin Alfa (activated). Journal of Emergency Nursing 2004;30:409.

Additional references

Abraham 2005
    1. Abraham E, Laterre PF, Garg R, Levy H, Talwar D, Trzaskoma BL, et al. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. New England Journal of Medicine 2005;353:1332‐41. - PubMed
Aird 2004
    1. Aird WC. Natural anticoagulant inhibitors: activated protein C. Best Practice and Research in Clinical Haematology 2004;17:161‐82. - PubMed
Angus 2003
    1. Angus DC, Linde‐Zwirble WT, Clermont G, Ball DE, Basson BR, Ely EW, Laterre PF, et al. Cost‐effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis. Critical Care Medicine 2003;31:1‐11. - PubMed
Balk 2004
    1. Balk RA. Optimum treatment of severe sepsis and septic shock: evidence in support of the recommendations. Disease‐A‐Month 2004;50:168‐213. - PubMed
Bell 1978
    1. Bell MJ, Ternberg JL, Feigin RD, Keating JP, Marshall R, Barton L, Brotherton T. Neonatal necrotizing enterocolitis. Therapeutic decisions based upon clinical staging. Annals of Surgery 1978;187:1‐7. - PMC - PubMed
Bernard 2001
    1. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez‐Rodriquez A, et al. Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Efficacy and safety of recombinant human activated protein C for severe sepsis. New England Journal of Medicine 2001;344:699‐709. - PubMed
Bernard 2004
    1. Bernard GR, Margolis BD, Shanies HM, Ely EW, Wheeler AP, Levy H, Wong K, et al. Extended evaluation of recombinant human activated protein C United States Trial (ENHANCE US): a single‐arm, phase 3B, multicenter study of drotrecogin alfa (activated) in severe sepsis. Chest 2004;125:2206‐16. - PubMed
Bone 1992
    1. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992;101:1644‐55. - PubMed
Carcillo 2002
    1. Carcillo JA, Fields AI, American College of Critical Care Medicine Task Force Committe Members. Clinical practice parameters for hemodynamic support of pediatric and neonatal patients in septic shock. Critical Care Medicine 2002;30:1365‐78. - PubMed
Carcillo 2003
    1. Carcillo JA. Pediatric septic shock and multiple organ failure. Critical Care Clinics 2003;19:413‐40. - PubMed
Carr 2005
    1. Carr R, Modi N, Dore C. G‐CSF and GM‐CSF for treating or preventing neonatal infections. Cochrane Database of Systematic Reviews 2005, Issue 3. [DOI: 10.1002/14651858.CD003066] - DOI - PMC - PubMed
Catalan 2004
    1. Catalan Agency for Health Technology Assessment and Research (CAHTA). Assessment of the scientific evidence on the use of recombinant activated C protein ‐ (activated) alpha‐drotrecogin ‐ in severe sepsis. Catalan agency for health technology assessment and research. Barcelona, 2004; Vol. 34. [http://www.mrw.interscience.wiley.com/cochrane/clhta/articles/HTA‐200403... HTA‐20040341]
Cesana 2010
    1. Cesana BM, Antonelli P, Chiumello D, Gattinoni L. Positive end‐expiratory pressure, prone positioning, and activated protein C: a critical review of meta‐analyses. Minerva Anestesiology 2010;76:929‐36. - PubMed
Dalton 2003
    1. Dalton HJ. Recombinant activated protein C in pediatric sepsis. Pediatric Infectious Disease Journal 2003;22:743‐5. - PubMed
De Carolis 2008
    1. Carolis MP, Polimeni V, Papacci P, Lacerenza S, Romagnoli C. Severe sepsis in a premature neonate: protein C replacement therapy. Turkish Journal of Pediatrics 2008;50:405‐8. - PubMed
De Carolis 2010
    1. Carolis MP. Use of protein C concentrate in neonatal period. Minerva Pediatrics 2010;62:29‐30. - PubMed
Deans 2004
    1. Deans KJ, Minneci PC, Banks SM, Natanson C, Eichacker PQ. Substantiating the concerns about recombinant human activated protein C use in sepsis. Critical Care Medicine 2004;32:2542‐43. - PubMed
Decembrino 2010
    1. Decembrino L, DAngelo A, Manzato F, Solinas A, Tumminelli F, Silvestri A, et al. Protein C concentrate as adjuvant treatment in neonates with sepsis‐induced coagulopathy: a pilot study. Shock 2010;34:341‐5. - PubMed
Dellinger 2004
    1. Dellinger RP, Carlet JM, Masur H, Gerlach H, Calandra T, Cohen J, et al. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Critical Care Medicne 2004;32:858‐73. - PubMed
Dellinger 2008
    1. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Critical Care Medicine 2008;36:296‐327. - PubMed
Edwards 2002
    1. Edwards MS. Postnatal bacterial infections. In: Fanaroff AA, Martin RJ editor(s). Neonatal‐Perinatal Medicine: Diseases of the fetus and infant. Seventh. St Louis: Mosby, 2002:706‐45.
Eichacker 2003
    1. Eichacker PQ, Natanson C. Recombinant human activated protein C in sepsis: inconsistent trial results, an unclear mechanism of action and safety concerns resulted in labeling restrictions and the need for phase IV trials. Critical Care Medicine 2003;31:S94‐6. - PubMed
EMEA 2002
    1. European Agency for the evaluation of medicinal products: committee for proprietary medicinal products. European public assessment report (EPAR) ‐ Xigris. www.emea.eu.int/pdfs/human/opinion/13844705en.pdf , www.emea.eu.int/pdfs/human/press/pr/12130705en.pdf. London, 2002.
European Medicines Agency (EMA) 2011
    1. European Medicines Agency (EMA). Xigris (drotrecogin alfa (activated)) to be withdrawn due to lack of efficacy. www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2011/10/... 2011, issue Accessed 15 February, 2012.
FDA 2002
    1. Food and Drug Administration: Anti‐Infective Advisory Committee. FDA Clinical Review: Drotrecogin Alfa (activated) [recombinant human activated protein C (rhAPC)] Xigris, BLA # 125029/0. www.fda.gov/cder/biologics/review/droteli112101r1.pdf www.fda.gov/medwatch/safety/2005/Xigris_dearhcp_4‐21‐05.pdf , www.fda.gov/medwatch/safety/2005/safety05.htm, www.fda.gov/ohrms/dockets/ac/01/minutes/3797m1.doc. Rockville, 2002:1‐161.
FDA 2011a
    1. US Food, Drug Administration. FDA Drug Safety Communication. Voluntary market withdrawal of Xigris [drotrecogin alfa (activated)] due to failure to show a survival benefit. www.fda.gov/DrugsSafety/ucm277114.htm accessed February 15, 2012.
FDA 2011b
    1. US Food, Drug Administration. Xigris [drotrecogin alfa (activated)]: Market withdrawal ‐ Failure to show survival benefit. www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedica... 2011; Vol. accessed 15 February, 2012.
Finfer 2008
    1. Finfer S, Ranieri VM, Thompson BT, Barie PS, Dhainaut JF, Douglas IS, et al. Design, conduct, analysis and reporting of a multi‐national placebo‐controlled trial of activated protein C for persistent septic shock. Intensive Care Medicine 2008;34:1935‐47. - PMC - PubMed
Fowler 2003
    1. Fowler R A, Hill‐Popper M, Stasinos J, Petrou C, Sanders G D, Garber A M. Cost‐effectiveness of recombinant human activated protein C and the influence of severity of illness in the treatment of patients with severe sepsis. Journal of Critical Care 2003;18:181‐91. - PubMed
Gentry 2009
    1. Gentry CA, Gross KB, Sud B, Drevets DA. Adverse outcomes associated with the use of drotrecogin alfa (activated) in patients with severe sepsis and baseline bleeding precautions. Critical Care Medicine 2009;37:19‐25. - PubMed
Girbes 2003
    1. Girbes AR, Polderman KH. A definite role for treatment with activated protein C in sepsis? Standard use is premature. Journal of Thrombosis and Haemostasis 2003;1:2469‐71. - PubMed
Gluck 2004
    1. Gluck T, Opal SM. Advances in sepsis therapy. Drugs 2004;64:837‐59. - PubMed
Goldstein 2006
    1. Goldstein B, Nadel S, Peters M, Barton R, Machado F, Levy H, et al. ENHANCE: results of a global open‐label trial of drotrecogin alfa (activated) in children with severe sepsis. Pediatric Critical Care Medicine 2006;7:200‐11. - PubMed
Goldstein 2005
    1. Goldstein B, Giroir B, Randolph A, International Consesnus Conference on Pediatric Sepsis. International pediatric sepsis consensus conference: definitions for sepsis and organ dysfunction in pediatrics. Pediatric Critical Care Medicine 2005;6:2‐8. - PubMed
Green 2005
    1. Green C, Dinnes J, Takeda A, Shepherd J, Hartwell D, Cave C, Payne E, et al. Clinical effectiveness and cost‐effectiveness of drotrecogin alfa (activated) (Xigris) for the treatment of severe sepsis in adults: a systematic review and economic evaluation. Health Technology Assessment 2005;9:1‐126, iii‐xiii. - PubMed
Haque 2005
    1. Haque K, Mohan P. Pentoxifylline for neonatal sepsis. Cochrane Database of Systematic Reviews 2005, Issue 3. [DOI: 10.1002/14651858.CD004205] - DOI - PubMed
Healy 2002
    1. Healy DP. New and emerging therapies for sepsis. Annals of Pharmacotherapeutics 2002;36:648‐54. - PubMed
Horbar 2001
    1. Horbar JD, Rogowski J, Plsek PE, Delmore P, Edwards WH, Hocker J, et al. Collaborative quality improvement for neonatal intensive care. NIC/Q Project Investigators of the Vermont Oxford Network. Pediatrics 2001;107:14‐22. - PubMed
Hotchkiss 2003
    1. Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. New England Journal of Medicine 2003;348:138‐50. - PubMed
Jagneaux 2004
    1. Jagneaux T, Taylor DE, Kantrow SP. Coagulation in sepsis. American Journal of Medical Science 2004;328:196‐204. - PubMed
Kapur 2002
    1. Kapur R, Yoder MC, Polin RA. Developmental Immunology. In: Fanaroff AA, Martin RJ editor(s). Neonatal‐Perinatal Medicine: Diseases of the Fetus and Infant. Seventh. Vol. 2, St Louis: Mosby, 2002:676‐706.
Klein 2001
    1. Klein JO. Bacterial Sepsis and Meningitis. In: Remington JS, Klein JO editor(s). Infectious Diseases of the Fetus and Newborn Infant. Fifth. Philadelphia: Saunders WB, 2001:943‐98.
Knaus 1985
    1. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Critical Care Medicine 1985;13:818‐29. - PubMed
Kutko 2003
    1. Kutko MC, Calarco MP, Flaherty MB, Helmrich RF, Ushay HM, Pon S, et al. Mortality rates in pediatric septic shock with and without multiple organ system failure. Pediatric Critical Care Medicine 2003;4:333‐7. - PubMed
Lauterbach 1999
    1. Lauterbach R, Pawlik D, Kowalczyk D, Ksyinski W, Helwich E, Zembala M. Effect of immunomodulating agent, pentoxifylline, in the treatment of sepsis in prematurely delivered infants: a placebo controlled, double‐blind trial. Critical Care Medicine 1999;27:807‐14. - PubMed
Levi 2007
    1. Levi M, Levy M, Williams MD, Douglas I, Artigas A, Antonelli M, et al. Prophylactic heparin in patients with severe sepsis treated with drotrecogin alfa (activated). American Journal of Respiratory and Critical Care Medicine 2007;176:483‐90. - PubMed
Levi 2011
    1. Levi M. Treatment with recombinant human activated protein C: one size does not fit all. Critical Care Medicine 2011;15:105. - PMC - PubMed
Levy 2003
    1. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Critical Care Medicine 2003;31:1250‐6. - PubMed
Lewis 2001
    1. Lewis DB, Wilson CB. Developmental immunology and role of host defenses in fetal and neonatal susceptibility to infection. In: Remington JS, Klein JO editor(s). Infectious Diseases of the Fetus and Newborn Infant. Fifth. Philadelphia: Saunders WB, 2001:25‐139.
Lilly 2011
    1. Lilly. Lilly Announces Withdrawal of Xigris® Following Recent Clinical Trial Results. https://investor.lilly.com/releasedetail2.cfm?ReleaseID=617602 2011, issue accessed 15 February 2011.
Lukacs 2004
    1. Lukacs LL, Schoendorf KC, Schuchat A. Trends in sepsis‐related neonatal mortality in the United States, 1985‐1998. Pediatric Infectious Diseases Journal 2004;23:599‐603. - PubMed
Manns 2002
    1. Manns BJ, Lee H, Doig CJ, Johnson D, Donaldson C. An economic evaluation of activated protein C treatment for severe sepsis. New England Journal Medicine 2002;347:993‐1000. - PubMed
Marshall 2004
    1. Marshall JC. Sepsis: current status, future prospects. Current opinion in Critical Care 2004;10:250‐64. - PubMed
Marti‐Carvajal 2011
    1. Marti‐Carvajal AJ, Sola I, Lathyris D, Cardona AF. Human recombinant activated protein C for severe sepsis. Cochrane Database of Systematic Reviews 2011, Issue 4. [DOI: 10.1002/14651858.CD004388.pub4] - DOI - PubMed
Medve 2005
    1. Medve L, Csitari IK, Molnar Z, Laszl A. Recombinant human activated protein C treatment of septic shock syndrome in a patient at 18th week of gestation: a case report. American Journal of Obstetrics and Gynecology 2005;193:864‐5. - PubMed
Network 1993
    1. The International Neonatal Network. The CRIB (clinical risk index for babies) score: a tool for assessing initial neonatal risk and comparing performance of neonatal intensive care units. The International Neonatal Network. Lancet 1993;342(885):193‐8. - PubMed
NICE 2004
    1. National Institute for clinical excellence. Drotrecogin alfa (activated) for severe sepsis. Technology Appraisal Guidance (www.nice.org.uk/TA084guidance) 2004; Vol. 84:1‐31.
O'Brien 2003
    1. O'Brien JM Jr, Abraham E. New approaches to the treatment of sepsis. Clinics in Chest Medicine 2003;24:521‐48. - PubMed
Ohlsson 2004a
    1. Ohlsson A, Lacy JB. Intravenous immunoglobulin for preventing infection in preterm and/or low‐birth‐weight infants. Cochrane Database of Systematic Reviews 2004, Issue 1. [DOI: 10.1002/14651858.CD005248.pub2] - DOI - PubMed
Ohlsson 2004b
    1. Ohlsson A, Lacy J. Intravenous immunoglobulin for suspected or subsequently proven infection in neonates. Cochrane Database of Systematic Reviews 2010, Issue 3. [DOI: 10.1002/14651858.CD001239.pub3] - DOI - PubMed
Opal 2007
    1. Opal SM. Can we RESOLVE the treatment of sepsis?. Lancet 2007;369:803‐4. - PubMed
Papile 1978
    1. Papile LA, Burstein J, Burstein R, Koffler H. Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1,500 gm. Journal of Pediatrics 1978;92:529‐34. - PubMed
Parker 2004
    1. Parker MM, Hazelzet JA, Carcillo JA. Pediatric considerations. Critical Care Medicine 2004;32:S591‐4. - PubMed
Parker 2005
    1. Parker MM. Pediatric definitions for sepsis: it's about time!. Pediatric Critical Care Medicine 2005;6:83‐4. - PubMed
Pettenazzo 2004
    1. Pettenazzo A, Malusa T. Use of protein C concentrate in critical conditions: clinical experience in pediatric patients with sepsis. Minerva Anestesiologica 2004;70:357‐63. [MEDLINE: ] - PubMed
Pollack 1996
    1. Pollack MM, Patel KM, Ruttimann UE. PRISM III: an updated Pediatric Risk of Mortality score. Critical Care Medicine 1996;24:743‐52. - PubMed
PROWESS SHOCK Steering Committee 2010
    1. PROWESS SHOCK Steering Committee, Thompson BT, Ranieri VM, Finfer S, Barie PS, Dhainault JF, et al. Statistical analysis plan for PROWESS SHOCK study. Intensive Care Medicine 2010;36:1972‐3. - PMC - PubMed
Ranieri 2011
    1. Ranieri VM, Thompson BT, Finfer S, Barie PS, Dhainaut JF, Douglas IS, et al. Unblinding plan of PROWESS‐SHOCK trial. Intensive Care Medicine 2011;37:1384‐5. - PubMed
Rice 2004
    1. Rice TW, Bernard GR. Drotrecogin alfa (activated) for the treatment of severe sepsis and septic shock. American Journal of Medical Science 2004;328:205‐14. - PubMed
Rice 2005
    1. Rice TW, Bernard GR. Therapeutic intervention and targets for sepsis. Annual Review of Medicine 2005;56:225‐48. - PubMed
Richardson 2001
    1. Richardson DK, Corcoran JD, Escobar GJ, Lee SK. SNAP‐II and SNAPPE‐II: Simplified newborn illness severity and mortality risk scores. Journal of Pediatrics 2001;138:92‐100. - PubMed
Shann 1997
    1. Shann F, Pearson G, Slater A, Wilkinson K. Pediatric index of mortality (PIM): a mortality prediction model for children in intensive care unit. Intensive Care Medicine 1997;23:201‐7. - PubMed
Shorr 2010
    1. Shorr AF, Janes JM, Artigas A, Tenhunen J, Wyncoll DL, Mercier E, et al. Randomized trial evaluating serial protein C levels in severe sepsis patients treated with variable doses of drotrecogin alfa (activated). Critical Care 2010;14:R229. - PMC - PubMed
Stoll 1998
    1. Stoll BJ, Holman RC, Schuchat A. Decline in sepsis‐associated neonatal and infant deaths in the United States, 1979 through 1994. Pediatrics 1998;102:e18. - PubMed
Stoll 2002
    1. Stoll BJ, Hansen N, Fanaroff AA, Wright LL, Carlo WA, Ehrenkranz RA, et al. Changes in pathogens causing early‐onset sepsis in very‐low‐birth‐weight infants. New England Journal of Medicine 2002;347:240‐7. - PubMed
Stoll 2003
    1. Stoll BJ, Hansen N. Infections in VLBW infants: studies from the NICHD Neonatal Research Network. Seminars in Perinatology 2003;27:293‐301. - PubMed
Stoll 2004
    1. Stoll BJ, Hansen NI, Adams‐Chapman I, Fanaroff AA, Hintz SR, Vohr B, Higgins RD, National Institute of Child Health and Human Development Neonatal Research Network. Neurodevelopmental and growth impairment among extremely low‐birth‐weight infants with neonatal infection. Journal of American Medical Association 2004;292:2357‐65. - PubMed
Sweeney 2009
    1. Sweeney DA, Natanson C, Eichacker PQ. Recombinant human activated protein C, package labeling, and hemorrhage risk. Critical Care Medicine 2009;37:327‐9. - PubMed
Toussaint 2009
    1. Toussaint S, Gerlach H. Activated protein C for severe sepsis. New England Journal of Medicine 2009;361:2646‐52. - PubMed
Vincent 1996
    1. Vincent JL, Moreno R, Takala J, Willatts S, Mendonca A, Bruining H, et al. The SOFA (Sepsis‐related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis‐Related Problems of the European Society of Intensive Care Medicine. Intensive Care Medicine 1996;22:707‐10. - PubMed
Vincent 2003
    1. Vincent J‐L, Light B, Wright TJ. Global ENHANCE results indicate organ function improvement with drotrecogin alfa (activated) in severe sepsis patients. Chest 2003;124:103S.
Vincent 2005
    1. Vincent JL, Bernard GR, Beale R, Doig C, Putensen C, Dhainaut JF, et al. Drotrecogin alfa (activated) treatment in severe sepsis from the global open‐label trial ENHANCE: further evidence for survival and safety and implications for early treatment. Critical Care Medicine 2005;33:2266‐77. - PubMed
Warren 2002
    1. Warren HS, Suffredini AF, Eichacker PQ, Munford RS. Risks and benefits of activated protein C treatment for severe sepsis. New England Journal of Medicine 2002;347:1027‐30. - PubMed
Watson 2003
    1. Watson RS, Carcillo JA, Linde‐Zwirble WT, Clermont G, Lidicker J, Angus DC. The epidemiology of severe sepsis in children in the United States. American Journal of Respiratory and Critical Care Medicine 2003;167:695‐701. - PubMed
Weigand 2004
    1. Weigand MA, Hörner C, Bardenheuer HJ, Bouchon A. The systemic inflammatory response syndrome. Best Practice and Research Clinical Anaesthesiology 2004;18:455‐75. - PubMed
Yan 2001
    1. Yan SB, Helterbrand JD, Hartman DL, Wright TJ, Bernard GR. Low levels of protein C are associated with poor outcome in severe sepsis. Chest 2001;120:915‐22. - PubMed
Zimmerman 2011
    1. Zimmerman JJ, Williams MD. Adjunctive corticosteroid therapy in pediatric severe sepsis: observations from the RESOLVE study. Pediatric Critical Care Medicine 2011;12:2‐8. - PubMed
Zuppa 2004
    1. Zuppa AF, Nadkarni VM. Recent developments in the pharmacological approach to pediatric critical care. Current Opinion in Anaesthesiology 2004;17:223‐8. - PubMed

References to other published versions of this review

Kylat 2006
    1. Kylat RI, Ohlsson A. Recombinant human activated protein C for severe sepsis in neonates. Cochrane Database of Systematic Reviews 2006, Issue 2. [DOI: 10.1002/14651858.CD005385.pub2] - DOI - PubMed

Publication types

MeSH terms